Corpus Intelligence IC Memo — HAMPDEN MEDICAL CENTER 2026-04-26 09:34 UTC
IC Memo — HAMPDEN MEDICAL CENTER
Investment Committee Memorandum | PA | 110 beds | Grade D | EBITDA uplift $2.0M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

HAMPDEN MEDICAL CENTER

CCN 390336 | nan, PA | 110 beds | April 26, 2026
EBITDA BridgeData Room
D
Investability

1. Target Overview & Investment Thesis

HAMPDEN MEDICAL CENTER is a 110-bed under-performing / distressed in nan, PA with $26.7M in net patient revenue and a -100.0% operating margin. The hospital serves a payer mix of 19.5% Medicare, 2.5% Medicaid, and 77.9% commercial.

Thesis: Undervalued. Our ML models identify $2.0M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -100.0% to -109.9% (+736bps).

Net Revenue HCRIS$26.7M
Current EBITDA COMPUTED$-31.3M
Operating Margin COMPUTED-100.0%
Occupancy HCRIS24.7%
Revenue / Bed COMPUTED$243K
Net-to-Gross HCRIS25.8%
Distress Probability ML54.2%

2. Market Context & Competitive Position

225
PA Hospitals
-4.4%
State Median Margin
102
Comparable Hospitals

PA has 225 Medicare-certified hospitals with a median operating margin of -4.4%. The target's margin of -100.0% places it below the state median. Among 102 size-comparable peers (55-220 beds), the median margin is -5.4%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (55-220), prioritizing same-state peers. 102 hospitals in the comp set.

HospitalStateBedsRevenueMargin
HAMPDEN MEDICAL CENTER (Target)PA110$26.7M-100.0%
ST LUKE HOSPITAL ANDERSON CAMPPA193$433.0M20.6%
THE GETTYSBURG HOSPITALPA76$341.8M18.4%
ST. JOSEPH MEDICAL CENTERPA132$334.8M13.2%
EPHRATA COMMUNITY HOSPITALPA115$291.8M3.8%
EINSTEIN MEDICAL CENTER MONTGOPA175$276.3M6.9%
THE GOOD SAMARITAN HOSPITALPA145$269.5M-5.0%
WILKES-BARRE GENERAL HOSPITALPA188$262.1M-13.0%
UPMC ST MARGARETPA185$248.5M-21.3%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $2.0M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$561K+210bp18mo
Cost to Collect4.5%2.5%$534K+200bp12mo
Denial Rate Reduction12.0%6.5%$529K+198bp12mo
A/R Days Reduction5200.0%3800.0%$325K+122bp9mo
Clean Claim Rate88.0%96.0%$17K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$561K
Cost to Collect
$534K
Denial Rate Reduction
$529K
A/R Days Reduction
$325K
Clean Claim Rate
$17K
Total EBITDA Uplift$2.0M
Current EBITDA$-31.3M
+ RCM Uplift+$2.0M
Pro Forma EBITDA$-29.3M
Current Margin-100.0%
Pro Forma Margin-109.9%
WC Released (1x)$1.0M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-48.2M$-186.8M0.00x-100.0%
Base (11x exit)10.0x11.0x$-48.2M$-221.1M0.00x-100.0%
Bull Case9.0x11.0x$-43.3M$-230.3M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-43.3M$-264.0M0.00x-100.0%
Bear Case11.0x10.0x$-53.0M$-181.0M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-53.0M$-216.3M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
MediumLow occupancyAt 24.7%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case
HighElevated distress probabilityModel estimates 54.2% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 102 hospitals with 55-220 beds
  • Same-state prioritization (n=103)
  • Comp margins: P25=-18.5% / P50=-5.4% / P75=7.8%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.